Biocryst Pharmaceuticals, Inc. Files Registration Statement for Public Offering.

BIRMINGHAM, Ala.--(BW HEALTHWIRE)--Sept. 24, 1999--

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it filed a registration statement with the Securities and Exchange Commission relating to a proposed public offering of 2,000,000 shares of its common stock. All of the shares are being offered by the Company. The managing underwriters for the offering are Salomon Smith Barney, Inc., Hambrecht & Quist LLC, and Raymond James & Associates, Inc.

BioCryst is a biotechnology company whose lead product candidate is a neuraminidase inhibitor designed to treat and prevent viral influenza.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.